Navigation Links
Regeneron Announces September 2012 Investor Conference Presentations
Date:8/29/2012

TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
  • Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012
  • UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use.  Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.

    Peter DworkinInvestor Relations

    Corporate Communications914-847-5126

    914.847.764manisha.narasimhan@regeneron.com 

    peter.dworkin@regeneron.com


    '/>"/>
    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    2. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    3. Regeneron Announces June 2012 Investor Conference Presentations
    4. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
    5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
    7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
    8. Misonix Announces New Distribution Agreement For Panama
    9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
    10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
    (Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
    (Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
    (Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
    (Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
    Breaking Medicine News(10 mins):